VRTX logo

Vertex Pharmaceuticals Incorporated

VRTX
Healthcare|Biotechnology|US
$547.09
+4.59 (+0.85%)
DCF Value
$349.13
Tangible Book / Share
$39.31
Graham Number
$170.60
Cash / Share
$24.87
Next Earnings Report
Feb 11, 2027
EPS est. $4.23 · Revenue est. $3.50B
Financing Filings (last 12 months)
0
No shelf registrations or offering prospectuses filed.

Upcoming Data Readouts (25)

Dec 2026
Est. completion
P1Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Absorption, Distribution, Metabolism, and Excretion of 14C-VX-407 After a Single Oral Dose
Dec 2026
Est. completion
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Polycystic Kidney Disease 1 (PKD1) Gene Variant Groups in Autosomal Dominant Polycystic Kidney Disease
Jan 2027
Est. completion
P3Diabetic Peripheral Neuropathic Pain
Evaluation of the Long-term Safety and Effectiveness of Suzetrigine (SUZ) in Participants With Painful Diabetic Peripheral Neuropathy (DPN)
Jan 2027
Est. completion
P4Pain
Evaluation of Pain Treatment After Total Knee Arthroplasty
Feb 2027
Est. completion
P1P2Myotonic Dystrophy Type 1 (DM1)
A Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1)
Mar 2027
Est. completion
P1Narcolepsy Type 1 (NT1)
A Phase 1, First-in-human Study of VX-433
Mar 2027
Est. completion
P1Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Effects of VX-407 on the Pharmacokinetics of Combined Oral Contraceptives
Mar 2027
Est. completion
P1P2Type 1 Diabetes
A Safety, Tolerability, and Efficacy Study of VX-264 in Participants With Type 1 Diabetes
Mar 2027
Est. completion
P2Diabetic Peripheral Neuropathic Pain
Evaluation of Efficacy and Safety of VX-993 for Pain Associated With Diabetic Peripheral Neuropathy
Apr 2027
Est. completion
P3Diabetic Peripheral Neuropathic Pain
Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral Neuropathy
Apr 2027
Est. completion
P3Cystic Fibrosis
Study to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508del
May 2027
Est. completion
P3Diabetic Peripheral Neuropathic Pain
Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy
Jun 2027
Est. completion
P3Sickle Cell Disease
Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Severe Sickle Cell Disease (SCD)
Jun 2027
Est. completion
P3Beta-Thalassemia
Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease
Jun 2027
Est. completion
P1Cystic Fibrosis
Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy Participants
Jul 2027
Est. completion
P1Cystic Fibrosis
Evaluation of VX-581 in Healthy Participants and in Participants With Cystic Fibrosis
Jul 2027
Est. completion
P2Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW)
Sep 2027
Est. completion
P3Cystic Fibrosis
Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis Participants 12 Months of Age and Older
Nov 2027
Est. completion
P3Beta-Thalassemia
Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Transfusion-Dependent β-Thalassemia (TDT)
Dec 2027
Est. completion
P3Diabetes Mellitus, Type 1
A Safety, Tolerability, and Efficacy Study of VX-880 and VX-017 in Participants With Type 1 Diabetes

Awaiting Results (2)

Trials past primary completion date but still active — data readout may be imminent.

Oct 2026
P3
A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy
NCT05444257
Oct 2026
P1
A Phase 1 Relative Bioavailability Study of a VX-581 Tablet Formulation
NCT07813039

SEC Filings (44)

Last two years from EDGAR. Insider Form 4s are on the Ownership tab.

FiledFormWhat it isLinks
Nov 3, 202610-QQuarterly reportDocumentIndex
Nov 2, 20268-KMaterial eventDocumentIndex
Oct 20, 20268-KMaterial eventDocumentIndex
Sep 1, 20268-KMaterial eventDocumentIndex
Aug 4, 202610-QQuarterly reportDocumentIndex
Aug 3, 20268-KMaterial eventDocumentIndex
Jul 7, 20268-KMaterial eventDocumentIndex
May 14, 2026SC 13G/APassive 5%+ stakeDocumentIndex
May 14, 2026SC 13G/APassive 5%+ stakeDocumentIndex
May 13, 2026S-8 POSEmployee stock planDocumentIndex
May 13, 2026S-8 POSEmployee stock planDocumentIndex
May 13, 2026S-8 POSEmployee stock planDocumentIndex
May 13, 2026S-8 POSEmployee stock planDocumentIndex
May 13, 2026S-8 POSEmployee stock planDocumentIndex
May 13, 2026S-8 POSEmployee stock planDocumentIndex
May 13, 2026S-8 POSEmployee stock planDocumentIndex
May 13, 2026S-8Employee stock planDocumentIndex
May 13, 20268-KMaterial eventDocumentIndex
May 5, 202610-QQuarterly reportDocumentIndex
May 4, 20268-KMaterial eventDocumentIndex
Apr 30, 2026SC 13GPassive 5%+ stakeDocumentIndex
Apr 29, 2026DEFA14AProxy / shareholder voteDocumentIndex
Apr 29, 20268-KMaterial eventDocumentIndex
Apr 2, 2026ARSAnnual report to holdersDocumentIndex
Apr 2, 2026DEFA14AProxy / shareholder voteDocumentIndex
Apr 2, 2026DEF 14AProxy / shareholder voteDocumentIndex
Mar 31, 20268-KMaterial eventDocumentIndex
Mar 27, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Feb 13, 202610-KAnnual reportDocumentIndex
Feb 12, 20268-KMaterial eventDocumentIndex
Feb 12, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Nov 4, 202510-QQuarterly reportDocumentIndex
Nov 3, 20258-KMaterial eventDocumentIndex
Aug 5, 202510-QQuarterly reportDocumentIndex
Aug 4, 20258-KMaterial eventDocumentIndex
May 19, 20258-KMaterial eventDocumentIndex
May 14, 20258-KMaterial eventDocumentIndex
May 13, 2025SC 13GPassive 5%+ stakeDocumentIndex
May 6, 202510-QQuarterly reportDocumentIndex
May 5, 20258-KMaterial eventDocumentIndex